A literature review of liver function test elevations in rifampin <scp>drug–drug</scp> interaction studies-Reference-Cited by-同舟云学术

A literature review of liver function test elevations in rifampin drug–drug interaction studies

Published:2022-05-09 Issue:7 Volume:15 Page:1561-1580
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Ibrahim Sherry M.¹,Pithavala Yazdi K.²,Vourvahis Manoli³,Chen Joseph⁴^ORCID

Affiliation:

1. Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego San Diego California USA

2. Clinical Pharmacology, Global Product Development Pfizer Inc. La Jolla California USA

3. Clinical Pharmacology, Global Product Development Pfizer Inc. New York New York USA

4. Clinical Pharmacology, Global Product Development Pfizer Inc. San Francisco California USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13281

Reference79 articles.

1. Rifampin Capsules USPU.S. Food & Drug Administration website. 2004. Accessed April 25 2022. www.accessdata.fda.gov/drugsatfda_docs/label/2004/50429s083lbl.pdf

2. Basic review of the cytochrome P450 system;McDonnell AM;J Adv Pract Oncol,2013

3. Pharmacokinetic Interactions with Rifampicin

4. Rifamycins (Rifampin, rifabutin, rifapentine);Drew RH;UpToDate.,2020

5. U.S. Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases Division of AIDSDivision of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1. Accessed April 25 2022.https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis;Expert Opinion on Drug Safety;2024-09-04

2. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer;Clinical Drug Investigation;2024-07-31

3. The Impact of N-nitrosamine Impurities on Clinical Drug Development;Journal of Pharmaceutical Sciences;2023-05

4. Molecular Factors and Pathways of Hepatotoxicity Associated with HIV/SARS-CoV-2 Protease Inhibitors;International Journal of Molecular Sciences;2023-04-27

5. Current management of liver diseases and the role of multidisciplinary approach;World Journal of Hepatology;2022-11-27